H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances

    H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as
                         Scientific Program Advances

PR Newswire

CAMBRIDGE, Mass., Nov. 26, 2012

CAMBRIDGE, Mass., Nov. 26, 2012 /PRNewswire/ -- Following a productive first
year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3),
a biopharmaceutical company specializing in the discovery and development of
oncology treatments, announced today that it has completed an expansion of its
headquarters and laboratory facilities in Cambridge, Massachusetts. The
increase more than doubles the company's original space to approximately
48,000 square feet, including new state-of-the-art laboratories, offices and
meeting rooms. The expansion will support an anticipated staff of 75
employees by the end of 2013, an increase in H3 Biomedicine's employee base of
29 in 2011.

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

"While we remain an early-stage, research-focused company, our rapid growth
this year marks a significant step toward developing novel oncology drug
candidates, and, ultimately, expediting the delivery of new therapies to the
patients who need them," said Markus Warmuth, M.D., President and Chief
Executive Officer of H3 Biomedicine. "Our unique corporate culture encourages
science-driven work and access to shared resources. We are fortunate to
attract top talent while operating in the Cambridge area, where the technical
expertise and entrepreneurial spirit are a strong fit for our organization."

In December 2011, H3 Biomedicine opened its headquarters in Cambridge with
24,000 square feet of working space. Eisai Co. Ltd., a research-based human
health care (hhc) company, pledged up to $200 million in research funding to
H3 Biomedicine and will provide additional support for the company's clinical
development programs, including access to many of Eisai's drug development
capabilities.

"Eisai's commitment is based on our recognition that H3 Biomedicine possesses
strong fundamentals in their science programs and innovative approach toward
cancer treatment development," said Haruo Naito, Eisai Co., Ltd. President and
CEO. "We are pleased that in this past year alone, the strong growth of their
research-based initiatives has brought us closer to the vision of realizing
the potential of personalized medicine."

Progress on Major Programs, Collaborations, Contribute to Expansion
H3 Biomedicine's leadership attributes the accelerated growth in large part to
the dedication of its scientists, including the bioinformatics team that is
driving its cancer genome mining work. These efforts aim to identify and
validate recurrent gene mutations that are potential targets for drug
therapies—the crucial first step in the company's mission to develop a library
of novel oncology candidates for clinical testing. Currently, H3 Biomedicine's
lead program is designed to develop drugs that target the gene SF3b1. Several
recent publications have implicated mutations in this gene in blood-related
malignant conditions, such as myelodysplastic syndromes and chronic
lymphocytic leukemia, as well as solid tumors like those associated with skin,
breast and pancreatic cancers. H3 plans to utilize its new facilities to
expand operations in pharmacokinetics and preclinical efficacy
studies—components crucial to H3's lead program.

H3 Biomedicine's world-class facilities and technology have also enabled
several key collaborations in 2012, including projects with Compendia
Bioscience and Horizon Discovery LTD. "These alliances have tremendous
synergy with our own scientific programs," continued Warmuth, "and our
expanded facilities will enable us to fulfill the programmatic requirements of
additional partnerships in which we participate."

About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery
and development of oncology treatments. Using modern synthetic chemistry,
chemical biology and human genetics, the company seeks to bring the next
generation of cancer treatments to market with the goal of improving the lives
of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit
http://www.H3biomedicine.com for more information.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
healthcare system. Eisai employs approximately 11,000 employees worldwide.

SOURCE H3 Biomedicine Inc.

Website: http://www.h3biomedicine.com
Contact: Mike Beyer, +1-773-463-4211, beyer@sambrown.com
 
Press spacebar to pause and continue. Press esc to stop.